QOLP-31. QUALITY OF LIFE OF PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA DURING TTFIELDS THERAPY IN ROUTINE CLINICAL CARE: FIRST RESULTS OF THE TIGER STUDY

Abstract

Background: Glioblastoma (GBM) is an aggressive primary tumor of the central nervous system. Current treatment strategies include maximal safe resection, followed by treatment with radiation and an alkylating chemotherapy. Based on the positive phase 3 trial EF-14, the addition of Tumor Treating Fields (TTFields) to temozolomide (TMZ) maintenance therapy brought an additional treatment method to clinical routine. The TIGER (TTFields In GErmany in Routine Clinical Care) study documents the use of TTFields in routine clinical care focusing on health-related quality of life (HRQoL), treatment compliance and duration. Methods: This multi-center prospective non-interventional study in Germany (NCT03258021) included ndGBM patients eligible for TTFields therapy. Following their consent to participate in the study, patients received a comprehensive introduction to the therapy and their baseline (BL) demographic data were collected. Information on TTFields therapy decision is evaluated based on a dedicated TTFields questionnaire at BL in both arms, follow-up information on how patients cope with the therapy is collected 2 months after TTFields treatment start, if applicable. HRQoL was assessed in patients deciding for TTFields therapy at BL as well as at 2 and 4 months thereafter using the EORTC-QLQ-C30/BN-20 questionnaires. Result: Between August 2017 and November 2019, 710 patients (259 female/451 male) were enrolled at 81 centers. The mean age was 58.5 years (range: 19.0-85.0). The overall BL characteristics of the study group reflects a typical GBM population. 582 (82%) decided to start TTFields and 128 (18%) refused TTFields treatment. HRQoL did not decline during TTFields therapy except for itchy skin, comparable to the results of the EF-14 phase 3 trial. A detailed analysis of the cohort as well as their reported QoL will be presented. Conclusion: The TIGER study is the largest non-interventional trial on the use of TTFields in routine clinical care. The use of TTFields in patients with ndGBM did not impair HRQoL during the follow-up period, except for more itchy skin.